A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness of Sublobar Dissection in the Chinese Patients With Non-small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03427567
• Other study ID #: TJ-LC-01
• Status: Completed
• Start date: December 1, 2017
• Est. completion date: March 30, 2018

Study information

• Verified date: May 2018
• Source: Tongji Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A study to evaluate effectiveness of sublobar dissection in patients with non-small cell lung cancer

Description:

This is a multi-centre real-world non-interventional observational study. The study data on patient demographic/tumor biological characteristics and clinical treatments were retrospectively collected to evaluate effectiveness of sublobar dissection in the Chinese patients with non-small cell lung cancer who received sublobar dissection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3902
• Est. completion date: March 30, 2018
• Est. primary completion date: December 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients >= 18 years old;

• Patients who received sublobar dissection from 2014 to 2017 (segment dissection/wedge dissection/segment and wedge dissections);

• Patients who received selective or systematic lymphadenectomy;

• Pathologically diagnosed patients with non-small cell lung cancer;

• Pathological staging: I, II

Exclusion Criteria:

• Patients who received cancer treatments before surgeries (adjuvant therapies including chemotherapies, radiotherapies, target therapies);

• Patients who received late-phase or intolerant palliative lobectomy or compromise sublobar dissection;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Procedure:
• Sublobar dissection
Sublobar dissection plus lymphadenectomy

Locations

Country	Name	City	State
China	China PLA General Hospital	Beijing	Beijing
China	China-Japan Friendship Hospital	Beijing	Beijing
China	Huaxi Hospital Affiliated to Sichuan University	Chengdu	Sichuan
China	First Hospital Affiliated to Zhejiang University	Hangzhou	Zhejiang
China	Jiangsu cancer hospital	Nanjing	Jiangsu
China	Shanghai Chest Hospital	Shanghai	Shanghai
China	Tianjin Chest Hospital	Tianjin	Tianjin
China	Tongji Hospital Affiliated to Huazhong Technology Hospital	Wuhan	Hubei
China	Xi'an Tangdu Hospital	Xi'an	Shaanxi
China	Henan cancer hospital	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Tongji Hospital	LinkDoc Technology (Beijing) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Impact factors of overall survival	Impact factors of overall survival as measured by patient demographic/tumor biological characteristics and clinical treatments	2014 - 2017
Other	Death rates after surgeries	Death rates after surgeries	2014 - 2017
Other	Impact factors of death rates after surgeries	Impact factors of death rates after surgeries	2014 - 2017
Other	Incidence of complications after surgeries	Incidence of complications after surgeries	2014 - 2017
Primary	Overall survival	Overall survival	2014 - 2017
Secondary	Overall survivals in subgroups	Overall survivals categorised by tumor biological characteristics	2014 - 2017